Please use this identifier to cite or link to this item:
|Title:||Serum IGF-binding protein-6 and prostate specific antigen in breast cancer|
|Authors:||Kaulsay, K.K. |
|Citation:||Kaulsay, K.K., Ng, E.H., Ji, C.Y., Ho, G.H., Aw, T.C., Lee, K.-O. (1999-02). Serum IGF-binding protein-6 and prostate specific antigen in breast cancer. European Journal of Endocrinology 140 (2) : 164-168. ScholarBank@NUS Repository.|
|Abstract:||Objective: Recent studies have demonstrated the presence of the IGF- binding proteins (IGFBPs) and prostate specific antigen (PSA), an IGFBP protease, in human breast tissue. We sought to investigate the differences in serum IGFs, IGFBP-1, -3 and -6, and PSA between patients with surgically proven breast cancer and patients with benign breast disease. Design and Methods: Concentrations of IGFs, IGFBP-1, -3 and -6, and PSA were determined in the sera from 57 patients with breast cancer (CA), and 46 women with benign breast disease (BBD) using immunoassays for IGFs and IGFBPs and an ultrasensitive ELISA for PSA. Results: The mean (± S.E.M.) serum IGFBP-6 level in the CA group, 127 (16) ng/ml, was statistically significantly lower than in the BBD group, 157 (10)ng/ml (P= 0.016). Patients with CA had an elevated geometric mean serum PSA level of 0.018 (range: 0.0015-0.107) ng/ml, compared with 0.007 (range: 0.0015-0.019) ng/ml in women with BBD (P=0.025). Mean serum IGFBP-1 concentrations were significantly lower in the CA group, 16 (2) ng/ml, versus 37 (4) ng/ml in the BBD group (P = 0.001). Mean serum IGFBP-3 concentrations were also lower in the CA group versus the BBD group, at 1981 (65) ng/ml, versus 2603 (140) ng/ml (P= 0.002) respectively. In the CA group, statistically significant correlations between PSA and IGFBP-6 (r=0.413; P=0.001), and between PSA and IGFBP-1 (r = -0.329; P = 0.021) were seen. Differences in IGF-I and -II between the two groups were not statistically significant. Conclusion: Lower serum concentrations of IGFBP- 6, -3 and -1, but higher PSA concentrations were seen in the breast cancer group, and collectively these would suggest that there is an increase in bioavailable IGF-I in breast cancer.|
|Source Title:||European Journal of Endocrinology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 3, 2018
WEB OF SCIENCETM
checked on Dec 31, 2018
checked on Dec 14, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.